CRNAO Stock Overview

A biotechnology company, develops novel circular RNA and immunotherapy medicines. More details

CRNAO fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	5/6
Past Performance	3/6
Financial Health	0/6
Dividends	0/6

Rewards

Trading at 99.8% below our estimate of its fair value

Earnings are forecast to grow 51.31% per year

Became profitable this year

Risk Analysis

Shares are highly illiquid

Shareholders have been substantially diluted in the past year

Debt is not well covered by operating cash flow

Negative shareholders equity

+ 2 more risks

My Notes

Capture your thoughts, links and company narrative

Circio Holding ASA Competitors

Bioventix

AIM:BVXP

UK£173.6m

Hindustan Bio Sciences

BSE:532041

₹110.2m

NeuroScientific Biopharmaceuticals

ASX:NSB

AU$4.9m

Genus

LSE:GNS

UK£994.5m

Price History & Performance

Summary of share price highs, lows and changes for Circio Holding
Historical stock prices
Current Share Price	NOK 2.52
52 Week High	NOK 0
52 Week Low	NOK 0
Beta	1.88
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	-98.47%
Change since IPO	-99.67%

Recent updates

Shareholder Returns

	CRNAO	GB Biotechs	GB Market
7D	0%	-5.1%	-2.2%
1Y	n/a	-24.5%	2.4%

Return vs Industry: Insufficient data to determine how CRNAO performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how CRNAO performed against the UK Market.

Price Volatility

Is CRNAO's price volatile compared to industry and market?
CRNAO volatility
CRNAO Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.0%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.5%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: CRNAO has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine CRNAO's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2010	8	Erik Wiklund	www.circio.com

Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023.

Circio Holding ASA Fundamentals Summary

How do Circio Holding's earnings and revenue compare to its market cap?
CRNAO fundamental statistics
Market cap	NOK 20.50m
Earnings (TTM)	NOK 9.50m
Revenue (TTM)	NOK 123.00k

2.2x

P/E Ratio

166.7x

P/S Ratio

Is CRNAO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CRNAO income statement (TTM)
Revenue	NOK 123.00k
Cost of Revenue	NOK 0
Gross Profit	NOK 123.00k
Other Expenses	-NOK 9.38m
Earnings	NOK 9.50m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.39
Gross Margin	100.00%
Net Profit Margin	7,722.76%
Debt/Equity Ratio	-81.1%

How did CRNAO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/09/17 05:13
End of Day Share Price	2024/06/20 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Circio Holding ASA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Arvid Necander	Carnegie Investment Bank AB
Geir Holom	DNB Markets
Jonas Peciulis	Edison Investment Research

Circio Holding BATS-CHIXE:CRNAO Stock Report